Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6815874 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2NAPEPLD | |
| SCHEMBL9488356 | 0.78 | CA12 (0.31) | — | |
| SCHEMBL460263 | 0.77 | SMN1; SMN2 (0.44) | SMN1; SMN2 | |
| SCHEMBL6262083 | 0.74 | SMN1; SMN2 (0.43) | SMN1; SMN2 | |
| SCHEMBL7340 | 0.73 | PGK1 (0.52) | SMN1; SMN2 | |
| SCHEMBL213379 | 0.73 | PGK1 (0.52) | SMN1; SMN2 | |
| SCHEMBL12284729 | 0.73 | SMN1; SMN2 (0.46) | SMN1; SMN2 | |
| SCHEMBL6655023 | 0.73 | PGK1 (0.52) | SMN1; SMN2 | |
| SCHEMBL14278848 | 0.73 | PGK1 (0.52) | SMN1; SMN2 | |
| SCHEMBL14278847 | 0.73 | PGK1 (0.52) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109880858-B | Method for reducing content of free fatty acid in marine phospholipid | 威海深蓝奇迹生物科技有限公司 | 2022-05-06 | — | — | CN | claimed |
| EP-3243509-B1 | OROBUCCAL ABSORPTION COMPOSITION FOR NEURO-PROTECTION | GRAAL S R L (IT) | 2019-04-17 | — | — | EP | claimed |
| EP-3243509-A1 | OROBUCCAL ABSORPTION COMPOSITION FOR NEURO-PROTECTION | Graal S.r.l. (IT) | 2017-11-15 | — | — | EP | claimed |
| EP-0354474-A2 | Method and composition for cryopreservation of tissue | Glonek, Thomas (US) | 1990-02-14 | — | — | EP | claimed |
| JP-1016890-A | — | — | None | — | — | JP | disclosed |
| US-12521407-B2 | Composition for use in prevention or reduction of oxidative stress and neurodegenerative diseases | RASI SIMO (FI) | 2026-01-13 | — | — | US | disclosed |
| CN-119053336-A | Compositions and methods for treating autoimmune disorders | 密执安大学评议会 | 2024-11-29 | — | — | CN | disclosed |
| CN-117209536-A | Glycerol phosphoryl ethanolamine series compound and lipid nano-drug carrier comprising same | 山东省药学科学院 | 2023-12-12 | — | — | CN | disclosed |
| US-20220193098-A1 | COMPOSITION FOR USE IN PREVENTION OR REDUCTION OF OXIDATIVE STRESS AND NEURODEGENERATIVE DISEASES | RASI SIMO (FI) | 2022-06-23 | — | — | US | disclosed |
| CN-109880858-B | Method for reducing content of free fatty acid in marine phospholipid | 威海深蓝奇迹生物科技有限公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3773012-A1 | COMPOSITION FOR USE IN PREVENTION OR REDUCTION OF OXIDATIVE STRESS AND NEURODEGENERATIVE DISEASES | Rasi, Simo (FI) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020212645-A1 | COMPOSITION FOR USE IN PREVENTION OR REDUCTION OF OXIDATIVE STRESS AND NEURODEGENERATIVE DISEASES | RASI SIMO (FI) | 2020-10-22 | — | — | WO | disclosed |
| EP-1220896-A4 | NOVEL HUMAN LIPASE PROTEINS, NUCLEIC ACIDS ENCODING THEM, AND USES OF BOTH OF THESE | MILLENIUM PHARMACEUTICALS INC (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-1220896-A1 | NOVEL HUMAN LIPASE PROTEINS, NUCLEIC ACIDS ENCODING THEM, AND USES OF BOTH OF THESE | MILLENIUM PHARMACEUTICALS, INC. (US) | 2002-07-10 | — | — | EP | disclosed |
| WO-2002024898-A2 | 47647, A HUMAN LIPASE AND USES THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| US-6268187-B1 | SUCH AS LYSOPHOSPHATIDYLETHANOLAMINE, BY ESTERIFICATION OR TRANSESTERIFICATION OF A GLYCEROL-3-PHOSPHATE DERIVATIVE WITH A FATTY ACID DERIVATIVE IN THE PRESENCE OF SALT HYDRATE PAIR(S) TO INCREASE THE REACTION RATE AND YIELD OF A LIPASE | DOOSAN CORPORATION (KR) | 2001-07-31 | — | — | US | disclosed |
| WO-2001025409-A1 | NOVEL HUMAN LIPASE PROTEINS, NUCLEIC ACIDS ENCODING THEM, AND USES OF BOTH OF THESE | MILLENIUM PHARMACEUTICALS, INCORPORATED (US) | 2001-04-12 | — | — | WO | disclosed |
| EP-0354474-A2 | Method and composition for cryopreservation of tissue | Glonek, Thomas (US) | 1990-02-14 | — | — | EP | disclosed |
| JP-S6416890-A | ANTIOXIDANT | SHISEIDO CO LTD | 1989-01-20 | — | — | JP | disclosed |
| CN-85104463-A | Produce the method for the phosphatldylcholine and the phosphatidyl ethanolamine that respectively carry different substituents | — | 1986-12-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193098-A1 | COMPOSITION FOR USE IN PREVENTION OR REDUCTION OF OXIDATIVE STRESS AND NEURODEGENERATIVE DISEASES | OTC, OAT, CRAT | SMN1; SMN2 150/4885NAPEPLD 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.